To Be Discontinued Injection Oncology
Pemetrexed Ditromethamine In · 421 days since initial FDA posting
FDA lists Pemetrexed Ditromethamine In as To Be Discontinued (Pfizer Inc.).
No availability text on this FDA row.
Pemetrexed Ditromethamine Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Pemetrexed Ditromethamine Injection
- Manufacturer
- Pfizer Inc.
- Dosage Form
- Injection
- Presentation
- Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)
- Package NDC
- 0409-1061-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jul 17, 2025
- Last Updated
- Jul 17, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug.
Nearby, Other Pemetrexed Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.